Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20252429 | 0.87 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1RAB9AESR1ACLY | |
| SCHEMBL16738668 | 0.87 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1RAB9AESR1ACLY | |
| SCHEMBL20239308 | 0.86 | SMN1; SMN2 (0.34) | SMN1; SMN2ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL20239142 | 0.86 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1ACLYGAAKMT2A | |
| SCHEMBL18249872 | 0.85 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1RAB9AESR1ACLY | |
| SCHEMBL20239280 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1RAB9AESR1ACLY | |
| SCHEMBL20239334 | 0.84 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1RAB9AESR1KMT2A | |
| SCHEMBL18249760 | 0.82 | PDE4B (0.39) | SMN1; SMN2ALDH1A1RAB9AESR1KMT2A | |
| SCHEMBL20239252 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1RAB9AESR1KMT2A | |
| SCHEMBL16738672 | 0.75 | PDE2A (0.36) | SMN1; SMN2ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10053429-B2 | DGAT2 inhibitors | ELI LILLY AND COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | SMN1; SMN2 4828/4885ALDH1A1 1430/4885RAB9A 1170/4885 |
| US-10053429-B2 | DGAT2 inhibitors | DGAT2, DGAT1, LCAT | SMN1; SMN2 4835/4885ALDH1A1 1189/4885RAB9A 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.